amrinone has been researched along with Inflammatory Response Syndrome, Systemic in 1 studies
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.
amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takeuchi, K | 1 |
| del Nido, PJ | 1 |
| Ibrahim, AE | 1 |
| Cao-Danh, H | 1 |
| Friehs, I | 1 |
| Glynn, P | 1 |
| Poutias, D | 1 |
| Cowan, DB | 1 |
| McGowan, FX | 1 |
1 other study available for amrinone and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
Vesnarinone and amrinone reduce the systemic inflammatory response syndrome.
Topics: Adjuvants, Immunologic; Amrinone; Animals; Drug Evaluation, Preclinical; Endotoxemia; Endotoxins; He | 1999 |